Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Apr;27(4):e70078.
doi: 10.1111/codi.70078.

A multicentre prospective single-arm clinical trial to evaluate the treatment outcomes of prophylactic laparoscopic lateral pelvic lymph node dissection for advanced lower rectal cancer

Affiliations
Observational Study

A multicentre prospective single-arm clinical trial to evaluate the treatment outcomes of prophylactic laparoscopic lateral pelvic lymph node dissection for advanced lower rectal cancer

Atsushi Hamabe et al. Colorectal Dis. 2025 Apr.

Abstract

Aim: There has been no prospective multicentre validation of the treatment outcomes of minimally invasive lateral pelvic lymph node dissection for lower rectal cancer; hence, this prospective study aimed to evaluate the treatment outcomes of prophylactic laparoscopic lateral pelvic lymph node dissection.

Method: Between May 2018 and August 2021, 90 patients with Stage II-III rectal cancer were registered. The clearance range for lateral pelvic lymph node dissection included the lymph nodes around the internal iliac artery and the obturator lymph nodes, while the autonomic nerves were generally preserved. The primary outcome was the incidence of Grade III-IV postoperative complications at discharge. The secondary outcomes were surgical and pathological outcomes, urinary function, sexual function, disease-free survival and overall survival. The experience of each facility and surgeon requirements were set to maintain quality control of lateral pelvic lymph node dissection.

Results: Of the 90 patients, 87 were analysed after exclusion of ineligible patients. There were 30 and 57 cases, respectively, of Stage II and III rectal cancer, among which 17 patients underwent neoadjuvant chemotherapy. The median operating time and blood loss were 472 min and 55 mL, respectively. Postoperative complications were observed in 22 patients (25.3%), and the primary outcome of Grade III postoperative complication was observed in five patients (5.7%). Eight lateral lymph nodes were harvested bilaterally, and lateral lymph node metastasis was observed in 14 patients.

Conclusion: Prophylactic lateral pelvic lymph node dissection can be safely performed with adequately quality-controlled laparoscopic procedures.

Keywords: laparoscopic surgery; lateral pelvic lymph node dissection; rectal cancer; short‐term outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests for this article.

Figures

FIGURE 1
FIGURE 1
Photographs showing the preservation level of the autonomic nerves and the clearance status of the lymph nodes. (A) Photograph after dissection of the obturator lymph nodes. (B) Photograph after dissection of the lymph nodes around the internal iliac artery. *, the external iliac vein; †, the external iliac artery; ‡, the internal iliac artery; #, the internal iliac vein; &, the obturator nerve; §, the ureter.

References

    1. Takemasa I, Hamabe A, Miyo M, Akizuki E, Okuya K. Essential updates 2020/2021: advancing precision medicine for comprehensive rectal cancer treatment. Ann Gastroenterol Surg. 2023;7(2):198–215. 10.1002/ags3.12646 - DOI - PMC - PubMed
    1. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22:29–42. 10.1016/S1470-2045(20)30555-6 - DOI - PubMed
    1. Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez‐Nebout N, et al. Neoadjuvant chemotherapy with folfirinox and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER‐PRODIGE 23): a multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22:702–715. 10.1016/S1470-2045(21)00079-6 - DOI - PubMed
    1. Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21:444–455. 10.1038/s41575-024-00900-9 - DOI - PMC - PubMed
    1. Petrelli F, Trevisan F, Cabiddu M, Sgroi G, Bruschieri L, Rausa E, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta‐analysis of treatment outcomes. Ann Surg. 2020;271(3):440–448. 10.1097/SLA.0000000000003471 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources